22 Mar 2024
PCRonline @ ACC.24 Scientific Sessions
The Interventional Cardiology perspective!
Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2024 Scientific Sessions #ACC24
Mirvat Alasnag, Luis Ortega-Paz, Aaysha Cader, Ali Nazmi Calik, Elad Asher, Luigi Biasco, Daniele Giacoppo, Nicola Ryan, Alessandro Sticchi and Panos Xaplanteris provide their take on what's new and what's hot in the field of interventional cardiology at ACC.24 and offer you condensed take-home messages, live from the congress. Discover their reviews below!
Late-breaking Clinical Trials and Science to be covered:
- The RELIEVE-HF study: is an atrial septal shunt beneficial in HFrEF?
- Empagliflozin after acute myocardial infarction: Results of the EMPACT-MI Trial - An interview with Javed Butler
- CSL112 (Apolipoprotein A-I) infusions and cardiovascular outcomes in patients with acute myocardial infarction (ApoA-I event reducing in ischemic syndromes II (AEGIS-II) Trial): Primary trial results - An interview with C. Michael Gibson
- Self-expanding versus balloon-expandable TAVR in patients with small aortic annuli: Primary outcomes from the randomized SMART Trial - An interview with Howard C. Herrmann
- Long-term beta-blocker treatment after acute myocardial infarction and preserved LVEF: The REDUCE-AMI Trial
- Percutaneous transvalvular micro-axial flow pump in infarct related cardiogenic shock: Results of the DANGER-shock Trial- An interview with Jacob Eifer Møller
- One-month ticagrelor monotherapy after PCI in acute coronary syndromes: Principal results from the double-blind, placebo-controlled Ultimate DAPT trial
- Coronary sinus reducer for the treatment of refractory angina: A randomised, placebo-controlled trial (ORBITA-COSMIC)- An interview with Rasha Al-Lamee and Michael Foley
- Transcatheter aortic valve implantation versus surgical aortic valve replacement in patients at low to intermediate risk: One-year outcomes of the randomized DEDICATE-DZHK6 Trial - An interview with Moritz Seiffert
- Effect of alcohol-mediated renal denervation on blood pressure in the presence of antihypertensive drugs: 3-month primary results from the TARGET BP I Randomized Trial - An interview with David E. Kandzari
- Preventive PCI or medical therapy alone for atherosclerotic coronary vulnerable plaques (PREVENT)
- Fractional flow reserve-guided complete or culprit-only PCI in patients with ST-elevation myocardial Infarction - FULL-REVASC
- Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes: The multicenter, randomized, blinded, IVUS-ACS Trial
- Protein and exercise to reverse frailty in older men and women undergoing transcatheter aortic valve replacement: The PERFORM-TAVR Trial
This independent ACC 2024 Coverage is available thanks to the unrestricted support of Medtronic
